U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Beauty Manufacturing Solutions Corp. - 535116 - 05/27/2021
  1. Warning Letters

CLOSEOUT LETTER

Beauty Manufacturing Solutions Corp. MARCS-CMS 535116 —

Delivery Method:
VIA Electronic Mail
Product:
Drugs
Recipient:
Recipient Name
Mr. Whoojong (Peter) I. Song
Recipient Title
CEO
Beauty Manufacturing Solutions Corp.

1250 Freeport Pkwy
Coppell, TX 75019
United States

psong@beautymanufacture.com
Issuing Office:
Dallas District Office

United States

Dear Mr. Song:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (CMS No. 535116) dated January 12, 2018 and our meeting with you on December 12, 2018. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
John W. Diehl, M.S.
Commander, U.S. Public Health Service
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Back to Top